Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: A study of a large blood donor population

Gut

Volumn 59, Issue 10, 2010, Pages 1389-1393

  Yuen, Man Fung ^a   Lee, Cheuk Kwong ^b   Wong, Danny Ka Ho ^a   Fung, James ^a   Hung, Ivan ^a   Hsu, Axel ^a   But, David Yiu Kuen ^a   Cheung, Ting Kin ^a   Chan, Pierre ^a   Yuen, John Chi Hang ^a   Fung, Frederic Khe Cheong ^a   Seto, Wai Kay ^a   Lin, Che Kit ^b   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HOSPITAL AUTHORITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; LIVER ENZYME; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD DONOR; CHRONIC HEPATITIS; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HONG KONG; HUMAN; LIVER BIOPSY; MALE; OCCULT HEPATITIS B; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROLOGY; VIRUS LOAD; BLOOD; BLOOD TRANSFUSION; COHORT ANALYSIS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HETEROZYGOTE; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD DONORS; BLOOD TRANSFUSION; CARRIER STATE; COHORT STUDIES; DNA, VIRAL; ENDEMIC DISEASES; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; MALE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 77957190181     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.209148     Document Type: Article

References (35)

1. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001;1:232-41.
2. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004;11:18-25.
3. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
4. Reesink HW, Engelfriet CP, Henn G, et al. Occult hepatitis B infection in blood donors. Vox Sang 2008;94:153-66.
5. Georgiadou SP, Zachou K, Rigopoulou E, et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat 2004;11:358-65.
6. Song EY, Yun YM, Park MH, et al. Prevalence of occult hepatitis B virus infection in a general adult population in Korea. Intervirology 2009;52:57-62.
7. Bhatti FA, Ullah Z, Salamat N, et al. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion 2007;47:74-9.
8. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis B. J Hepatol 1995;22:696-9.
9. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-9.
10. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8.
11. Kleinman SH, Strong DM, Tegtmeier GG, et al. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005;45:1247-57.
12. Owusu-Ofori S, Temple J, Sarkodie F, et al. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 2005;45:133-40.
13. Li L, Chen PJ, Chen MH, et al. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion 2008;48:1198-206.
14. Luo KX, Zhou R, He C, et al. Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen. J Med Virol 1991;35:55-9.
15. Shih LN, Sheu JC, Wang JT, et al. Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol 1990;32:257-60.
16. Wang JT, Wang TH, Sheu JC, et al. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991;163:397-9.
17. Coste J, Reesink HW, Engelfriet CP, et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang 2005;88:289-303.
18. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000;40:1165-8.
19. Velati C, Fomiatti L, Baruffi L, et al. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill 2005;10:12-14.
20. Seed CR, Cheng A, Ismay SL, et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002;42:1365-72.
21. Murokawa H, Yoshikawa A, Ohnuma H, et al. Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testing. Vox Sang 2005;88:10-16.
22. Laperche S. Blood safety and nucleic acid testing in Europe. Euro Surveill 2005;10:3-4.
23. Stramer SL. US NAT yield: where are we after 2 years? Transfus Med 2002;12:243-53.
24. Baginski I, Chemin I, Hantz O, et al. Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis. Transfusion 1992;32:215-20.
25. Thiers V, Lunel F, Valla D, et al. Post-transfusional anti-HCV-negative non-A non-B hepatitis (II) serological and polymerase chain reaction analysis for hepatitis C and hepatitis B viruses. J Hepatol 1993;18:34-9.
26. Hoofnagle JH, Seeff LB, Bales ZB, et al. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978;298:1379-83.
27. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98.
28. La'ulu SL, Roberts WL. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am J Clin Pathol 2006;125:748-51.
29. Jeantet D, Chemin I, Mandrand B, et al. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 2004;73:508-15.
30. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6.
31. Bréchot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'? Hepatology 2001;34:194-203.
32. Yeoh EK, Chang WK, Kwan JPW. Epidemiology of viral hepatitis B infection in Hong Kong. In: Lam SK, Lai CL, Yeoh EK, eds. Viral hepatitis B infection in the Western Pacific region: vaccine and control. Singapore: World Scientific, 1984:33-41.
33. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694-701.
34. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599-608.
35. Tabor E, Purcell RH, Gerety RJ. Primate animal models and titered inocula for the study of human hepatitis A, hepatitis B, and non-A, non-B hepatitis. J Med Primatol 1983;12:305-18.